adamantane has been researched along with glimepiride in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 24 (82.76) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Banerji, MA; Baron, MA; Camisasca, RP; Couturier, A; Ebeling, P; Foley, JE; Garber, AJ; Gudbjörnsdottir, S | 1 |
| Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B | 1 |
| Barnett, AH | 1 |
| Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B | 1 |
| Couturier, A; Goodman, M; Haneda, M; Inaba, Y; Kikuchi, M; Koya, D; Mimori, N; Onishi, Y; Tobe, K | 1 |
| Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B | 1 |
| Jermendy, G | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Berndt-Zipfel, C; Dworak, M; Forst, T; Klamp, I; Löffler, A; Mitry, M; Pfützner, A | 1 |
| Bader, G; Geransar, P; Schweizer, A | 1 |
| Berndt-Zipfel, C; Dworak, M; Forst, T; Löffler, A; Michelson, G; Mitry, M; Pfützner, A | 1 |
| Forst, T; Foteinos, G; He, YL; Kulmatycki, K; Mattapalli, D; Neelakantham, S; Taylor, A | 1 |
| Kothny, W; Kozlovski, P; Li, Y; Lukashevich, V; Lv, X; Ma, J; Sun, F; Wang, W; Woloschak, M; Xing, X; Yang, W; Yuan, G | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 2 |
| Chi, J; Gu, W; Hong, J; Ning, G; Wang, B; Wang, W; Zhang, Y | 1 |
| Durán-Garcia, S; Hanefeld, M; Hardy, E; Langslet, G; Malvolti, E; Niskanen, L; Östgren, CJ; Schernthaner, G | 1 |
| Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L | 1 |
| Geissel, W | 1 |
| Cho, YM; Jang, HC; Jung, HS; Kim, SY; Kwak, S; Park, KS | 1 |
| Cook, W; Hirshberg, B; Ohman, P; Perl, S; Wei, C | 1 |
| Hur, KY; Jin, SM; Kim, G; Kim, JH; Lee, MK; Oh, S | 1 |
| Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D | 1 |
| Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L | 1 |
| Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS | 1 |
| Kaundal, PK; Mokta, JK; Mokta, K; Sahai, AK | 1 |
| Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA | 1 |
| Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH | 1 |
2 review(s) available for adamantane and glimepiride
| Article | Year |
|---|---|
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin | 2009 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
25 trial(s) available for adamantane and glimepiride
| Article | Year |
|---|---|
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2008 |
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin | 2009 |
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2010 |
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
Topics: Adamantane; Aged; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vildagliptin | 2010 |
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2010 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
Topics: Adamantane; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2013 |
Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
Topics: Adamantane; Aged; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain | 2013 |
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Erythrocyte Deformability; Female; Germany; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Laser-Doppler Flowmetry; Male; Metformin; Microcirculation; Middle Aged; Nitriles; Pyrrolidines; Regional Blood Flow; Retinal Vessels; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Young Adult | 2013 |
Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prognosis; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Young Adult | 2015 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intention to Treat Analysis; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Weight Loss | 2014 |
Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2015 |
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Topics: Adamantane; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2015 |
[New attempt in a benefit evaluation].
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds | 2015 |
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.
Topics: Adamantane; Cardiovascular Diseases; Chemokine CXCL12; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Vildagliptin | 2017 |
Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds; Treatment Outcome | 2016 |
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2017 |
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections | 2018 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Weight Gain | 2019 |
Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Quality of Life; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2018 |
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2022 |
2 other study(ies) available for adamantane and glimepiride
| Article | Year |
|---|---|
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Hospital Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Insurance Claim Review; Kidney Diseases; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2015 |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
Topics: Adamantane; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phosphatidylcholines; Sulfonylurea Compounds; Treatment Outcome | 2019 |